Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sage-324 in Essential Tremor (KINETIC)
NCT04305275Phase 2Completed
- Sponsor
- Sage Therapeutics
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential tremor (ET) comparing Sage-324 with Placebo (2 arms). Primary endpoint: The Essential Tremor Rating Assessment Scale Performance Subscale Part 4 Upper Limb Tremor Score at Day 29. Started May 2020; status: completed.
02
Drugs
sage-324
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT04305275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305275.